Stem cell transplantation for multiple myeloma: current and future status.

Area of Science:

• Hematology
• Oncology
• Stem Cell Research

Background:

• Stem cell transplantation (SCT) is a cornerstone in multiple myeloma (MM) treatment.
• Advances in MM therapies necessitate re-evaluation of SCT's role.
• Optimal induction and post-transplantation strategies require clarification.

Purpose of the Study:

• To review the current role and optimal use of SCT in multiple myeloma.
• To discuss the impact of novel agents on SCT efficacy and safety.
• To identify areas for future research in SCT for MM.

Main Methods:

• Review of existing literature on SCT for multiple myeloma.
• Analysis of the influence of novel agents (bortezomib, lenalidomide, thalidomide) on SCT outcomes.
• Evaluation of tandem autologous and allogeneic SCT in the context of current MM treatment paradigms.

Main Results:

• Bortezomib- or lenalidomide-based induction therapy is recommended for eligible patients.
• The role of tandem autologous SCT is unclear due to prior studies predating novel agents.
• Allogeneic SCT is under investigation and may benefit select patients with donors.
• Post-transplantation consolidation and maintenance with novel agents can improve outcomes for non-responders.

Conclusions:

• SCT remains vital for MM, but its integration with novel agents needs refinement.
• Post-transplantation maintenance therapy is crucial for prolonging remission and survival.
• Further research is essential to optimize SCT strategies, patient selection, and safety in MM treatment.